Related Experiment Videos
[The expression technology of chimeric and humanized antibodies]
1First Department of Internal Medicine, Sapporo Medical University.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 22, 2002
Summary
Monoclonal antibodies (MoAbs) show promise for treating diseases like cancer. Genetic engineering has overcome limitations of early MoAbs, leading to chimeric, humanized, and fully human antibody therapies.
Area of Science:
- Immunology
- Biotechnology
- Therapeutic antibodies
Context:
- Monoclonal antibodies (MoAbs) discovered in 1975 offer potential for treating cancer, viral infections, and autoimmune disorders.
- Early murine MoAbs faced limitations including immune responses and inadequate human effector function activation.
- Significant advancements in MoAb technology over 25 years have addressed these challenges.
Purpose:
- To review the evolution of monoclonal antibody technology.
- To discuss strategies for developing improved antibody therapeutics.
- To highlight the overcoming of limitations in murine MoAbs.
Summary:
- Genetic engineering techniques have enabled the creation of chimeric mouse-human, CDR-grafted, and fully human antibodies.
- These advanced antibody formats overcome the immunogenicity and effector function issues associated with murine MoAbs.
- The review focuses on new strategies for developing these next-generation antibodies.
Impact:
- Enables the development of safer and more effective antibody-based therapies.
- Expands the therapeutic potential of monoclonal antibodies across various diseases.
- Represents a significant leap forward in antibody engineering for clinical applications.